McKesson completed its acquisition of RxCrossroads on Jan. 3.
Here are four things to know:
1. Originally announced on Nov. 6, 2017, McKesson completed the transaction valued at $735 million, funded by cash on hand.
2. The company expects its acquisition to enhance existing commercialization solutions for manufacturers of branded, specialty, genetic and biosimilar drugs. McKesson will grow its end-to-end offerings for manufacturers and add plasma logistics to its manufacturer services.
3. RxCrossroads' services include adherence support for manufacturers and patients they serve as well as streamlining the process from product launch through a course of therapy.
4. RxCrossroads is now part of McKesson Specialty Health and McKesson expects the transaction to be around 20 cents accretive to adjusted earnings per diluted share by the third year after the transaction closes.
"This investment will strengthen our existing best-in-class solutions, including hub services and patient assistance programs while establishing new logistics services to plasma manufacturers, which allows us to serve biopharma companies of all sizes throughout the product life cycle," said Chairman and CEO of McKesson John Hammergren.
More articles on supply chain:
8 statistics on ASC drug and medical supply cost per OR across the US
Medline acquires Centurion Medical Products—4 insights
3 trends in the healthcare supply chain management market